Publicação científica trimestral do CREMERJ

24 Novas fronteiras no diagnóstico e no tratamento da hipertensão arterial Wille Oigman Med. Ciên. e Arte , Rio de Janeiro, v.1, n.1, p.9-24, jan-mar 2022 5. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018; 71:1269-1324. doi: 10.1161/HYP.0000000000000066. 6. Diretrizes Brasileiras de Hipertensão Arterial – 2020. Arq Bras Cardiol: doi: org/10.36660/abc.20201238 7. Mancia G. Clinical significance of white-coat hypertension. J Hypertens. 2016;34(4):623–6. 8. Grossman E, Messerli FH. Drug-induced hypertension: an unappreciated cause of secondary hypertension. Am J Med. 2012;125(1):14-22. 9. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ. 2003;326(7404):1427. 10. Julius S. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE Randomised Trial. Lancet 2004 Jun 19;363(9426):2022-31. doi: 10.1016/S0140-6736(04)16451-9. 11. Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE, Kimmel PL, Johnson KC, Goff DC Jr, Fine LJ, Cutler JA, Cushman WC, Cheung AK, Ambrosius WT. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. SPRINT Research Group,.N Engl J Med. 2015 Nov 26;373(22):2103-16. doi: 10.1056/NEJMoa1511939. 12. Hansson L, Zanchetti A, Carruthers SG, et al, for the HOT Study Group. Effects of intensive blood- pressure lowering and low dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755–62. https://doi.org/10.1016/ S0140-6736(05)79283-7Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhäger WH, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet. 1997;350(9080):757-64 13. Dahlof B, Devereux R, Kjeldsen S, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the losartan intervention or endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet. 2002;359(9311):995-1003. 14. Beckett NS. Treatment of Hypertension in Patients 80 Years of Age or Older. N Engl J Med 2008; 358:1887- 1898 doi: 10.1056/NEJMoa0801369. 15. Sleight P, Redon J, Verdecchia P, Mancia G, Gao P, Fagard R, et al. ONTARGET investigators. Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. J Hypertens. 2009;27(7):1360-9. 16. OigmanW, Cordeiro HA, Benchimol AB, Quadra AA. Abandoment of treatment in arterial hypertension]. Arq Bras Cardiol. 1977;30(4):247-53.